{"id":4080,"date":"2016-08-25T10:50:35","date_gmt":"2016-08-25T14:50:35","guid":{"rendered":"https:\/\/medicarereport.org\/?p=4080"},"modified":"2016-08-25T10:50:35","modified_gmt":"2016-08-25T14:50:35","slug":"under-fire-mylan-takes-steps-to-make-600-epipen-more-affordable","status":"publish","type":"post","link":"https:\/\/medicarereport.org\/?p=4080","title":{"rendered":"Under fire, Mylan takes steps to make $600 EpiPen more affordable"},"content":{"rendered":"<p>(Ed Silverman for ST<em>A<\/em>T)<\/p>\n<p><span class=\"big-cap\">I<\/span>n the face of <a href=\"https:\/\/www.statnews.com\/2016\/08\/24\/ama-urges-epipen-manufacturer-rein-exorbitant-costs\/\" target=\"_blank\">withering criticism<\/a>, Mylan Pharmaceuticals\u00a0<a href=\"http:\/\/newsroom.mylan.com\/2016-08-25-Mylan-Taking-Immediate-Action-to-Further-Enhance-Access-to-EpiPen-Epinephrine-Injection-USP-Auto-Injector\" target=\"_blank\">took steps<\/a>\u00a0Thursday to make its\u00a0EpiPen\u00a0device more affordable. Specifically, the company is increasing the amount of money on a copay assistance card from $100 to $300, and is also widening eligibility for patients to receive the device through that\u00a0assistance program. <a href=\"https:\/\/www.statnews.com\/pharmalot\/2016\/08\/25\/mylan-epipen-clinton-drug-prices\/?_hsenc=p2ANqtz-_fgXeW0GpBb8lhqmicsW9lfBDLo85zGkHG_C2vJTZ4wBcqqO6sfSzqL-LUTVN8lgPCHad4Uzng3YP02DGPkmed0oVukw&amp;_hsmi=33405785\" target=\"_blank\">Continue reading article here&#8230;.<\/a><\/p>\n<pre><strong>Notice<\/strong>: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link\u2019s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.<\/pre>\n","protected":false},"excerpt":{"rendered":"<p>(Ed Silverman for STAT) In the face of withering criticism, Mylan Pharmaceuticals\u00a0took steps\u00a0Thursday to make its\u00a0EpiPen\u00a0device more affordable. Specifically, the<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[15],"tags":[],"class_list":["post-4080","post","type-post","status-publish","format-standard","hentry","category-part-dprescription-drugs"],"_links":{"self":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/4080","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=4080"}],"version-history":[{"count":1,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/4080\/revisions"}],"predecessor-version":[{"id":4081,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/4080\/revisions\/4081"}],"wp:attachment":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=4080"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=4080"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=4080"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}